Sugi Predict

Sugi Predict / Compounds / SCHEMBL6951995

SCHEMBL6951995

SCHEMBL6951995

COc1ccc(-c2ccccc2C#N)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.59
▸ POLB P06746 1/20 0.59
▸ GAA P10253 1/20 0.59
▸ ABL1 P00519 1/20 0.55
▸ ABCB1 P08183 1/20 0.55
▸ BCR P11274 1/20 0.55
▸ MEN1 O00255 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ NPC1 O15118 2/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ HDAC4 P56524 1/20 0.49
▸ HDAC2 Q92769 1/20 0.49
▸ HDAC8 Q9BY41 1/20 0.49
▸ STAT3 P40763 1/20 0.48
▸ PGR P06401 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20282675 0.88 POLB (0.54) ESR2POLBGAAABL1ABCB1
SCHEMBL31374641 0.84 ABL1 (0.58) ESR2POLBGAAABL1ABCB1
P-Anisic Acid SCHEMBL2903597 0.83 CA1 (0.56) GAAMEN1ALDH1A1KMT2AMAPT
SCHEMBL7689092 0.83 POLB (0.49) ESR2POLBGAAABL1ABCB1
SCHEMBL6957048 0.82 FFAR1 (0.55) ESR2POLBGAAABL1ABCB1
SCHEMBL31410710 0.82 ESR2 (0.76) ESR2GAAALDH1A1KDM4EAR
SCHEMBL7095254 0.81 PGR (0.55) POLBGAAABL1ABCB1BCR
SCHEMBL29662946 0.81 PGR (0.55) POLBGAAABL1ABCB1BCR
SCHEMBL21331583 0.81 ABL1 (0.55) POLBGAAABL1ABCB1BCR
SCHEMBL29616810 0.81 ABL1 (0.55) POLBGAAABL1ABCB1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114560790-B Biphenyl-2-nitrile compound and preparation method thereof 赣南师范大学 2024-02-20 — — CN disclosed
CN-117229154-A Preparation method of bifenazate intermediate 帕潘纳(北京)科技有限公司 2023-12-15 — — CN disclosed
CN-108699019-A Benzofuran derivatives useful in the treatment of central nervous system and other diseases 华纳巴布科克绿色化学学院有限公司 2018-10-23 — — CN disclosed
WO-2016184652-A9 METHODS FOR PRODUCING METALATED ORGANIC COMPOUNDS LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2017-08-10 — — WO disclosed
CN-102241553-B Method for preparing aromatic cross-coupled compound UNIV BEIJING 2013-08-07 — — CN disclosed
CN-102241553-A Method for preparing aromatic cross-coupled compound UNIV BEIJING 2011-11-16 — — CN disclosed
US-20050059827-A1 Process for the preparation of valsartan and intermediates thereof TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) 2005-03-17 — — US disclosed
EP-0711762-B1 PROCESS FOR PRODUCING TETRAZOLE COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2003-08-06 — — EP disclosed
US-6277998-B1 REACTING 2-CYANO-4-OXO-4H-BENZOPYRAN COMPOUND WITH HYDROGEN SULFIDE AND THEN REACTING PROUDCT WITH ALKYL HALIDE; REACTING THE PRODUCT WITH HYDRAZINE OR ITS SALT AND THEN WITH NITROUS ACID COMPOUND TO OBTAIN TETRAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-08-21 — — US disclosed
US-6191289-B1 REACTING A 4-OXO-4H-BENZOPYRAN GROUP SUBSTITUTED WITH AMIDE OR A PHENYL GROUP IN ITS 2 POSITION IS REACTED WITH ANHYDROUS HYDRAZINE OR SALT IN PRESENCE OF CATALYST FOLLOWED BY REACTING WITH NITROUS ACID OR SALT TO FORM TETRAZOLE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-20 — — US disclosed
US-5874593-A SULFUR CONTAINING AMIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1999-02-23 — — US disclosed
EP-0883603-A1 METHOD FOR PRODUCING UNSYMMETRICALLY SUBSTITUTED BIPHENYLS Great Lakes Chemical Konstanz GmbH (DE) 1998-12-16 — — EP disclosed
WO-1997030970-A1 METHOD FOR PRODUCING UNSYMMETRICALLY SUBSTITUTED BIPHENYLS GREAT LAKES CHEMICAL KONSTANZ GMBH (DE) 1997-08-28 — — WO disclosed
EP-0571770-B1 Method for producing an asymmetric biaryl derivative IHARA CHEMICAL IND CO (JP) 1996-07-10 — — EP disclosed
EP-0711762-A1 PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-15 — — EP disclosed
US-5380719-A Quinoxaline biphenyl angiotensin II inhibitors E. R. SQUIBB & SONS, INC. (US) 1995-01-10 — — US disclosed
US-5380910-A Dehalogeno coupling IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 1995-01-10 — — US disclosed
EP-0571770-A1 Method for producing an asymmetric biaryl derivative IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) 1993-12-01 — — EP disclosed
US-5262052-A Separation of polycyclic aromatic hydrocarbons BRIGHAM YOUNG UNIVERSITY (US) 1993-11-16 — — US disclosed
EP-0556060-A1 Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists E.R. SQUIBB & SONS, INC. (US) 1993-08-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059827-A1 Process for the preparation of valsartan and intermediates thereof REN, AGT, ACE ESR2 4094/4885POLB 1126/4885GAA 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.